Pharmaceutical

Karuna Therapeutics files for FDA approval for schizophrenia treatment

Karuna Therapeutics has announced the submission of a NDA to the FDA for KarXT (xanomeline-trospium) for the treatment of schizophrenia.

Sep 29, 2023 - 20:00
Karuna Therapeutics files for FDA approval for schizophrenia treatment
Karuna Therapeutics has announced the submission of a NDA to the FDA for KarXT (xanomeline-trospium) for the treatment of schizophrenia.
Read the original article

Tags:

Previous Article

Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies

Next Article

ModeX wins $168m BARDA contract to develop viral antibody therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

FDA approves BeiGene’s TEVIMBRA for oesophageal cancer

Mar 16, 2024

Opinion: Every smartphone should have an app to connect to 988, the mental health crisis line

Opinion: Every smartphone should have an app to connect...

Sep 22, 2023

STAT+: Ozempic 3.0? Lilly’s ‘triple-G’ drug shows biggest weight loss yet in mid-stage trial

STAT+: Ozempic 3.0? Lilly’s ‘triple-G’ drug shows bigge...

Jun 26, 2023